A Brighter Outlook for New Cystic Fibrosis Drugs
This article was originally published in Start Up
Executive Summary
The pipeline of new medicines to combat cystic fibrosis has risen dramatically thanks to funding support from philanthropic organizations such as the Cystic Fibrosis Foundation and venture capitalists. As more compounds demonstrate proof-of-concept, look for Big Pharma to move into the area too, lured by the possibility of label expansion beyond CF into more widespread diseases such as asthma and COPD.
You may also be interested in...
Inspire Extends Treatment In Phase III Trial For Disease-Modifying CF Candidate
Open-label safety extension of earlier Phase III study shows progressive improvement from baseline over time.
Inspire Extends Treatment In Phase III Trial For Disease-Modifying CF Candidate
Open-label safety extension of earlier Phase III study shows progressive improvement from baseline over time.
PTC Advances Cystic Fibrosis Candidate On Encouraging Data
Company is pursuing PTC124 in nonsense-mutation-mediated CF, a patient population of about 3,000 in the U.S.